Irfan Cinar, Muhammed Yayla, Muhammet Celik, Arzu Bilen, Zafer Bayraktutan
{"title":"内皮素1在人MCF-7细胞增殖和迁移中的作用","authors":"Irfan Cinar, Muhammed Yayla, Muhammet Celik, Arzu Bilen, Zafer Bayraktutan","doi":"10.5152/eurasianjmed.2020.20033","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to explore the role of endothelin 1 (ET-1) in human breast cancer proliferation and migration and antagonism of endothelin receptor A (ETAR) and endothelin receptor B (ETBR) by using the non-selective dual ETA/ETB receptor antagonist bosentan and determine its anti-proliferative, anti-metastatic, and apoptotic effects demonstrated by nuclear factor kappa B (NF-kB), vascular endothelial growth factor (VEGF), Caspase 3 and Caspase 9 expression on endothelin-induced proliferation of MCF-7 cell line in vitro.</p><p><strong>Materials and methods: </strong>A total of 8,000 cells were seeded into e-plates 24 hours after the cells were incubated with or without 10-4 M BOS (1 hour before ET-1 treatment); 10-7, 10-8, and 10-9 M ET-1 for 1-4 days.</p><p><strong>Results: </strong>Whether ET-1 is present or not in the tumor area, bosentan exerts anti-proliferative effect on breast cancer. However, ET-1 and bosentan group showed important inhibitory effect on tumor migration compared to bosentan alone, which can be attributed to increased activity of ET-1 axis in the presence of ET-1. The imbalance among the NF-kB, caspases, and VEGF, which are predictive factors of carcinogenesis significantly improved after bosentan administration.</p><p><strong>Conclusion: </strong>Our study definitely demonstrated ET-1 and its critical role in cancer progression with apoptotic and anti-apoptotic pathways (NF-κB) and VEGF expression, and migration analyses were also performed. The second major finding was that bosentan inhibited ET-1-mediated effects on tumor proliferation and migration.</p>","PeriodicalId":517142,"journal":{"name":"The Eurasian Journal of Medicine","volume":"52 3","pages":"277-282"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651758/pdf/eajm-52-3-277.pdf","citationCount":"4","resultStr":"{\"title\":\"Role of Endothelin 1 on Proliferation and Migration of Human MCF-7 Cells.\",\"authors\":\"Irfan Cinar, Muhammed Yayla, Muhammet Celik, Arzu Bilen, Zafer Bayraktutan\",\"doi\":\"10.5152/eurasianjmed.2020.20033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of this study was to explore the role of endothelin 1 (ET-1) in human breast cancer proliferation and migration and antagonism of endothelin receptor A (ETAR) and endothelin receptor B (ETBR) by using the non-selective dual ETA/ETB receptor antagonist bosentan and determine its anti-proliferative, anti-metastatic, and apoptotic effects demonstrated by nuclear factor kappa B (NF-kB), vascular endothelial growth factor (VEGF), Caspase 3 and Caspase 9 expression on endothelin-induced proliferation of MCF-7 cell line in vitro.</p><p><strong>Materials and methods: </strong>A total of 8,000 cells were seeded into e-plates 24 hours after the cells were incubated with or without 10-4 M BOS (1 hour before ET-1 treatment); 10-7, 10-8, and 10-9 M ET-1 for 1-4 days.</p><p><strong>Results: </strong>Whether ET-1 is present or not in the tumor area, bosentan exerts anti-proliferative effect on breast cancer. However, ET-1 and bosentan group showed important inhibitory effect on tumor migration compared to bosentan alone, which can be attributed to increased activity of ET-1 axis in the presence of ET-1. The imbalance among the NF-kB, caspases, and VEGF, which are predictive factors of carcinogenesis significantly improved after bosentan administration.</p><p><strong>Conclusion: </strong>Our study definitely demonstrated ET-1 and its critical role in cancer progression with apoptotic and anti-apoptotic pathways (NF-κB) and VEGF expression, and migration analyses were also performed. The second major finding was that bosentan inhibited ET-1-mediated effects on tumor proliferation and migration.</p>\",\"PeriodicalId\":517142,\"journal\":{\"name\":\"The Eurasian Journal of Medicine\",\"volume\":\"52 3\",\"pages\":\"277-282\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7651758/pdf/eajm-52-3-277.pdf\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Eurasian Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5152/eurasianjmed.2020.20033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Eurasian Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/eurasianjmed.2020.20033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
摘要
摘要目的:本研究旨在探讨内皮素1 (ET-1)在人乳腺癌增殖迁移中的作用,利用非选择性ETA/ETB受体拮抗剂波生坦对内皮素受体A (ETAR)和内皮素受体B (ETBR)的拮抗作用,并通过核因子κ B (NF-kB)、血管内皮生长因子(VEGF)、Caspase 3和Caspase 9表达对内皮素诱导MCF-7细胞体外增殖的影响。材料与方法:在ET-1处理前1小时,用10-4 M BOS或不加BOS孵育24小时,将8000个细胞接种于e-plate;10- 7,10 - 8,10 -9 M ET-1, 1-4天。结果:无论ET-1是否存在于肿瘤区域,波生坦对乳腺癌均有抗增殖作用。而ET-1和波生坦组相比单独波生坦组对肿瘤的迁移表现出重要的抑制作用,这可能是由于ET-1存在时,ET-1轴的活性增加。使用波生坦后,NF-kB、caspases和VEGF(致癌的预测因素)之间的失衡显著改善。结论:我们的研究明确了ET-1及其通过凋亡和抗凋亡通路(NF-κB)和VEGF的表达在癌症进展中的关键作用,并进行了迁移分析。第二个主要发现是波生坦抑制et -1介导的肿瘤增殖和迁移作用。
Role of Endothelin 1 on Proliferation and Migration of Human MCF-7 Cells.
Objective: The aim of this study was to explore the role of endothelin 1 (ET-1) in human breast cancer proliferation and migration and antagonism of endothelin receptor A (ETAR) and endothelin receptor B (ETBR) by using the non-selective dual ETA/ETB receptor antagonist bosentan and determine its anti-proliferative, anti-metastatic, and apoptotic effects demonstrated by nuclear factor kappa B (NF-kB), vascular endothelial growth factor (VEGF), Caspase 3 and Caspase 9 expression on endothelin-induced proliferation of MCF-7 cell line in vitro.
Materials and methods: A total of 8,000 cells were seeded into e-plates 24 hours after the cells were incubated with or without 10-4 M BOS (1 hour before ET-1 treatment); 10-7, 10-8, and 10-9 M ET-1 for 1-4 days.
Results: Whether ET-1 is present or not in the tumor area, bosentan exerts anti-proliferative effect on breast cancer. However, ET-1 and bosentan group showed important inhibitory effect on tumor migration compared to bosentan alone, which can be attributed to increased activity of ET-1 axis in the presence of ET-1. The imbalance among the NF-kB, caspases, and VEGF, which are predictive factors of carcinogenesis significantly improved after bosentan administration.
Conclusion: Our study definitely demonstrated ET-1 and its critical role in cancer progression with apoptotic and anti-apoptotic pathways (NF-κB) and VEGF expression, and migration analyses were also performed. The second major finding was that bosentan inhibited ET-1-mediated effects on tumor proliferation and migration.